pSiMedica is developing a new type of drug delivery system that is based on nanostructuring elemental silicon (BioSilicon™), a new biomaterial with broad potential application in medicine. The importance of pSiMedica of establishing innovative and worthwhile partnerships is evident from the manner in which the company was formed. This article focuses on the approach and the deals made through various levels of its business activities.